GlassScriptPhysician profile
Charles L Levison
NPI 1386604866
$240.86
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $83.11 · 2021: $32.51 · 2022: $22.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $37.76 | 2019-2020 | |
| Boston Scientific Corporation | $35.20 | 2020-2021 | |
| Medtronic USA, INC. | $26.77 | 2019 | |
| Abbvie INC. | $22.91 | 2022 | |
| Strongbridge US INC. | $16.94 | 2020 | |
| Novo Nordisk INC | $15.84 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.55 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.64 | 2020 | |
| Smith+Nephew, INC. | $14.52 | 2019 | |
| Lilly USA, LLC | $14.06 | 2019 | |
| Merck Sharp & Dohme LLC | $13.69 | 2019 | |
| Hologic Sales and Service, LLC | $12.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Levison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.